Logo
  • About us

  • Plasma

  • Products

  • Engagement

  • News

  • Careers

NUWIQ PUP Study

The largest prospective clinical trial of a single FVIII product in previously untreated patients with hemophilia A.

Review the NuProtect Study and Findings

News & stories

Check out our latest stories
2022-01-25
Press release
As Omicron Spreads Nationally, Octapharma’s fibryga® & Octaplas™ Become Increasingly Important Replacement Therapies
Medical Providers Should Consider Replacing Cryoprecipitate and Fresh Frozen Plasma with Octaplas™ and fibryga® if Supplies Become Depleted
2021-12-07
Press release
FDA Approves Octapharma’s cutaquig® 16.5% for Pediatric PI Patients, Providing Flexible Treatment Options
Families, Providers Can Utilize Flexible Infusion Schedule to Meet Patient Needs
2021-08-30
Press release
FDA Orphan Drug Approval: Octapharma’s Octagam® 10% Receives 7 Years of Market Exclusivity for Adult Dermatomyositis
Octagam® 10% Expected to Become the First Treatment Option for Adults with Rare Immune-mediated Inflammatory Disease
2021-07-20
Press release
FDA Approves Octapharma's Octagam®10% for Adult Dermatomyositis
FDA Approval Based on Positive Results of International, Multi-center ProDERM Study
Show more

Patient engagement

Octapharma takes an active role in our community

We sponsor and support organizations worldwide.
Learn how we engage with patients

Our products

Products

Learn more about our products to treat rare diseases and other coagulopathies and bleeding disorders.
Learn more

What can we help you find?


  • About us
  • About us

  • Who we are


  • Diseases & therapies


  • Research & development


  • Our locations

  • Plasma
  • Plasma

  • Products
  • Products

  • Our product portfolio


  • The production process


  • Quality & safety

  • Engagement
  • Engagement

  • Patient engagement


  • Events

  • News
  • News

  • Careers


  • Contact us


  • California required statements


  • Transparency in Coverage


© 2023 Octapharma USA, Inc.

© 2023 Octapharma USA, Inc.

Data privacy statement
Terms of use
Data privacy statement
Terms of use
LinkedIn OctapharmaYoutube Octapharma
LinkedIn OctapharmaYoutube Octapharma
Youtube Octapharma
LinkedIn Octapharma

OCTA-0286